Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
about
Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vectorImmunization delivered by lentiviral vectors for cancer and infectious diseases.Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors.Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth.Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunizationTyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patientsIndoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.Lentiviral vectors for immunization: an inflammatory field.Targeting lentiviral vectors for cancer immunotherapy.Lentiviral vectors for cancer immunotherapy and clinical applicationsEngineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.
P2860
Q34166320-E55D4C0C-ECE9-4CF4-8D36-9ABD9219AE7BQ34539879-7BA6AA6B-7969-4C51-977A-6C3276271B66Q34792987-FF1A662D-33A5-4ABC-8D6E-B5588CD0CB9DQ34801069-171CACA6-8F58-427F-ADEA-67B8AA431D8FQ34958663-9BBAF673-40E5-4CBD-8E18-9CBA465FDA9AQ35147489-E7D57A89-E271-4118-9B08-3CC247DEE514Q35799014-D20BBFF4-6F66-4195-BC84-4DA7814E19DCQ35982675-77ECF4FD-938D-469A-A801-3F821B2DEAEFQ36777149-EDCAEFA7-DD98-4CD3-BE70-5A269D3EDF18Q36863949-02CFC135-8FE4-4F58-8FB8-DDACA1066C9FQ36889688-C2E3A31B-E1A5-4501-9F4C-5AD4F03FE2E3Q37234611-BF82636C-F796-4B2B-949E-9D7583845858Q37635491-61AA0E56-BB2B-4EEC-B279-2FE8E12C0DCFQ37690581-EC10A180-5AF1-460D-9579-788D8AC4C468Q37706590-B36F3687-E03B-413C-B95A-74DFFCC309ADQ38043924-674E0577-B1DA-4AF9-832E-2F863B893A1CQ38147100-7613402A-2917-465F-8995-46FD33FE1F7DQ38231581-690837BA-3D6E-4D36-BF2E-7B755A23C2F0Q39549328-DE76388C-DB64-48F4-9EBA-4D558B19DBF5Q41955454-3CE935D8-0D32-4EA4-BF2A-5DD82ECFF908Q42124738-2E9E2C2C-9683-4E43-8672-0BAD85364DB1
P2860
Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lentivector immunization stimu ...... es antitumor immunity in mice.
@ast
Lentivector immunization stimu ...... es antitumor immunity in mice.
@en
Lentivector immunization stimu ...... es antitumor immunity in mice.
@nl
type
label
Lentivector immunization stimu ...... es antitumor immunity in mice.
@ast
Lentivector immunization stimu ...... es antitumor immunity in mice.
@en
Lentivector immunization stimu ...... es antitumor immunity in mice.
@nl
prefLabel
Lentivector immunization stimu ...... es antitumor immunity in mice.
@ast
Lentivector immunization stimu ...... es antitumor immunity in mice.
@en
Lentivector immunization stimu ...... es antitumor immunity in mice.
@nl
P2093
P2860
P356
P1476
Lentivector immunization stimu ...... tes antitumor immunity in mice
@en
P2093
Jose Guevara-Patino
Michael Mi
Yanjun Liu
Yibing Peng
P2860
P304
P356
10.4049/JIMMUNOL.0900008
P407
P577
2009-05-01T00:00:00Z